Use of acridinium-based photocatalyst in the Giese-type coupling of arylboronic acids with electron poor olefins
Caldarelli M, Loriz L, Piazza L, Caputo G, DeAmici M, Papeo G Tetrahedron Letters (2022) 103, 153978
Stereoselective synthesis of 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as PIM kinase inhibitors inspired from marine alkaloids
Casuscelli F, Ardini E, Avanzi N, Badari A, Casale E, Disingrini T, Donati D, Ermoli A, Felder E, Galvani A, Isacchi A, Menichincheri M, Montemartini M, Orrenius C, Piutti C, Salom B, Papeo G Chirality (2022), 34(11), 1437-1452
BL-01, an Fc-bearing, tetravalent CD20 × CD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo
Interdonato A, Choblet S, Sana M, Valgardsdottir R, Cribioli S, Alzani R, Roth M, Duonor-Cerutti M, Golay J Cytotherapy (2022), 24(2), 161-171
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours
Schöffski P, Awada A, de la Bigne A, Felloussi Z, Burbridge M, Cantero F, Colombo R, Maruzzelli S, Ammattatelli K, de Jonge M, Aftimos P, Dumez H, Sleijfer S Eur J Cancer (2022), 169 (135-145)
Nerviano Medical Sciences S.r.l. Expands US Presence
Nerviano Medical Sciences S.r.l. (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today that it has expanded its presence in the US with the creation of a new US subsidiary, Nerviano Medical Sciences Inc. Nerviano Medical Sciences Inc. is incorporated […]
Nerviano Medical Sciences S.r.l. Announces First Patient Dosed in Phase 1 Clinical Trial of NMS-812 for The Treatment of Relapsed Refractory Multiple Myeloma (MM).
Nerviano Medical Sciences S.r.l., a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, recently announced that the first patient has been dosed in its Phase 1 clinical trial of NMS-812 in adult patients with relapsed refractory Multiple Myeloma (MM). NMS-812 is a novel potent […]
NMS Group S.p.A. has approved the 2021 Financial Statements with positive outlook for 2022
The Board of Directors of NMS Group S.p.A has approved today the company’s annual financial report, including the consolidated financial statements of the Group as of 31 December 2021. “2021 was a challenging yet rewarding year for our Group. As we firmly believe in our mission to discover and develop life-changing molecules to patients, we […]
European Journal of Cancer this month published an article on the FIH study in patients with solid tumors conducted with the MPS1 compound NMS-01940153E discovered at NMS S.r.l.
Nerviano, 13 May 2022 MPS1, also known as monopolar spindle 1, is a protein kinase which is over-expressed and hyperactivated in different tumors and which plays a critical role in the control of mitosis (cell division) by regulating a process called the Spindle Assembly Checkpoint. NMS Srl started the MPS1 inhibitor program, which resulted in […]
Nerviano Medical Sciences announces new organizational structure and management team including key appointments
Nerviano, 5 May 2022 Nerviano Medical Sciences (NMS Srl,) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancers, today announces the new organizational structure and key appointments of the new management team, effective immediately. The new organizational structure is designed to: Reposition the company’s […]
A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response
Gambardella G, Viscido G, Tumaini B, Isacchi A, Bosotti R, di Bernardo D Nat Commun (2022), 13(1), 1714